At ImaginAb, we are developing our own pipeline of targeted imaging agents for disease states which currently have limited clinical diagnostic tools.  We will take these novel diagnostic imaging agents into the clinic and through FDA registration to allow for in vivo phenotyping of patients enhancing personalized detection, treatment, and monitoring of disease progression.  We know the potential for PET imaging to be expanded to novel targets and strive to address unmet clinical needs and improve patient outcomes. 

Prostate Stem Cell Antigen (PSCA)

Indication: Prostate, Bladder, Pancreatic Cancer

Shortly commencing Phase I clinical studies at UCLA under physician sponsored IND

 

J591 Prostate-Specific Membrane Antigen (PSMA)

Indication: Prostate Cancer

Currently initiating cGMP manufacturing/toxicology studies

 

T-cell co-receptor (CD8)

Indication: Cancer, inflammation, and transplantation

Currently undergoing pre-clinical imaging studies

ImaginAb’s products have not yet received FDA marketing clearance in the US or equivalent regulatory clearance in non-US territories.